These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17389556)

  • 1. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
    Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
    J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
    Lefèvre G; Pommier F; Sedek G; Allison M; Huang HL; Kiese B; Ho YY; Appel-Dingemanse S
    J Clin Pharmacol; 2008 Feb; 48(2):246-52. PubMed ID: 18199897
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs.
    Shen C; Yang B; Zhou T; Duan G; Yu Y
    Pharmazie; 2011 Aug; 66(8):590-3. PubMed ID: 21901981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rivastigmine patch for dementia.
    Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
    [No Abstract]   [Full Text] [Related]  

  • 9. Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditions.
    Raynaud JP; Augès M; Liorzou L; Turlier V; Lauze C
    Int J Pharm; 2009 Jun; 375(1-2):28-32. PubMed ID: 19481687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.
    Lefèvre G; Büche M; Sedek G; Maton S; Enz A; Lorch U; Sagan C; Appel-Dingemanse S
    J Clin Pharmacol; 2009 Apr; 49(4):430-43. PubMed ID: 19246725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
    Burian R
    MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.